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Abstract
Background: The contributions of brain cannabinoid (CB) receptors, typically CB1 (CB type 1) receptors, to the
behavioral effects of nicotine (NC) have been reported to involve brain transient receptor potential vanilloid 1
(TRPV1) receptors, and the activation of candidate endogenous TRPV1 ligands is expected to be therapeutically
effective. In the present study, the effects of TRPV1 ligands with or without affinity for CB1 receptors were
examined on NC-induced depression-like behavioral alterations in a mouse model in order to elucidate the
“antidepressant-like” contributions of TRPV1 receptors against the NC-induced “depression” observed in various
types of tobacco abuse.
Results: Repeated subcutaneous NC treatments (NC group: 0.3 mg/kg, 4 days), like repeated immobilization stress
(IM) (IM group: 10 min, 4 days), caused depression-like behavioral alterations in both the forced swimming
(reduced swimming behaviors) and the tail suspension (increased immobility times) tests, at the 2 h time point
after the last treatment. In both NC and IM groups, the TRPV1 agonists capsaicin (CP) and olvanil (OL) administered
intraperitoneally provided significant antidepressant-like attenuation against these behavioral alterations, whereas
the TRPV1 antagonist capsazepine (CZ) did not attenuate any depression-like behaviors. Furthermore, the
endogenous TRPV1-agonistic CB1 agonists anandamide (AEA) and N-arachidonyldopamine (NADA) did not have
any antidepressant-like effects. Nevertheless, a synthetic “hybrid” agonist of CB1 and TRPV1 receptors, arvanil (AR),
caused significant antidepressant-like effects. The antidepressant-like effects of CP and OL were antagonized by the
TRPV1 antagonist CZ. However, the antidepressant-like effects of AR were not antagonized by either CZ or the CB1
antagonist AM 251 (AM).
Conclusions: The antidepressant-like effects of TRPV1 agonists shown in the present study suggest a characteristic
involvement of TRPV1 receptors in NC-induced depression-like behaviors, similar to those caused by IM. The strong
antidepressant-like effects of the potent TRPV1 plus CB1 agonist AR, which has been reported to cause part of its
TRPV1-mimetic and cannabimimetic effects presumably via non-TRPV1 or non-CB1 mechanisms support a
contribution from other sites of action which may play a therapeutically important role in the treatment of NC abuse.
Background
Nicotine (NC) is the addictive substance in tobacco which
results in increased use among adolescents and numerous
harmful health effects have been reported for both males
and females [1-3]. Its ability to alter the level of mood (e.g.
depression, anxiety, etc.) is a characteristic of NC, as pre-
viously reviewed [4,5]. Depression is one of the most fre-
quently-observed psychiatric symptoms associated with
NC abuse, and has been reported mainly as a withdrawal
symptom which occurs in dependent smokers [6,7].
Furthermore, in some daily smokers, direct depressant
effects, which disappear soon after the cessation of smok-
ing, have also been reported, and this is consistent with
some animal experimental data [8-10]. On the other hand,
in some clinical cases, brief antidepressant-like effects are
observed during the period immediately after transdermal
NC patch treatment [11]. The occurrence of both depres-
sant and antidepressant effects seems to be one of the
characteristics of NC-induced behavioral responses, and
this occurrence of reduced depression has been postulated
to reinforce the habitual use of NC, based on a review of
clinical cases [12].
NC-induced “depression-like” behavioral alterations in
animal experimental models have been quantified as Correspondence: thayase@mri.biglobe.ne.jp
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forced swimming test [9,10,13]. This test is used for
screening antidepressants, which suppress immobility in
swimming behaviors [14]. On the other hand, various
stressors such as immobilization stress (IM) are known
to cause depression-like behaviors, as represented by
exacerbated immobility in swimming behaviors [15,16].
Repeated NC administration also caused exacerbated
immobility in these behavioral tests [9,10,13].
In the author’s preliminary studies, NC-induced
depression-like behavioral alterations in mice were
reduced by some antidepressants, which have been used
to treat major depression and to antagonize brain nicoti-
nic acetylcholine receptors (nAChRs), the direct targets
of NC [10,17,18]. The effects of such antidepressants
have recently been characterized by their ability to cause
neurogenesis in the hippocampus [19,20]. Brain cannabi-
noid (CB) receptors, typically CB1 (CB type 1) receptors,
can be considered one of the potent “antidepressant” tar-
gets of NC, based on their contribution to neurogenesis
in the hippocampus via endogenous ligands [21,22] and
the NC-altered levels of endogenous CB1 ligands in the
brain including the hippocampus [23]. A direct contribu-
tion of CB1 receptors to some NC-induced alterations in
locomotor activities was demonstrated by experiments
using CB1 knockout mice [24]. In addition to CB1 recep-
tors, recent immunohistochemical and behavioral studies
have shown that transient receptor potential vanilloid 1
(TRPV1) receptors in the basal ganglia also interact with
some endogenous CB1 ligands, and contribute to aber-
rant behaviors such as prolonged hypokinesia [25-28].
There have been few studies on the contribution of
TRPV1 receptors to NC-induced behavioral effects,
although antidepressant actions have been demonstrated
for TRPV1 agonists such as olvanil [29]. Furthermore, the
existence of a number of “candidate” endogenous TRPV1
ligands, which are expected to provide therapeutic effects
against pathological conditions such as behavioral disor-
ders, has been reported [30,31]. In the present study,
based on the involvement of TRPV1 receptors in the
effects of CB1 ligands, the functional relationship between
nAChRs and TRPV1 receptors [32], and the author’s preli-
minary data on the antidepressant-like effects of some
cannabimimetics against NC-induced depression-like
behaviors [10], the effects of TRPV1 ligands with or with-
out affinity for CB1 receptors were examined against NC-
and IM-induced depression-like behaviors in mice. Since
few references on the depression-related behavioral altera-
tions caused by TRPV1 ligands are available, the TRPV1
ligands were selected from those which provided some
behavioral effects upon intraperitoneal or intravenous
injections: the prototypic agonist capsaicin (CP) [33], the
potent and antidepressant agonist olvanil (OL) [29], the
antagonist capsazepine (CZ) [29], the endogenous TRPV1-
agonistic CB1 agonists anandamide (arachidonylethanola-
mide: AEA) [27] and N-arachidonyldopamine (NADA)




Based on a previous study on stressor treatments [16],
male ICR mice (80 ± 10 days old) (Shizuoka Laboratory
Animal Center, Hamamatsu, Japan) were housed in a
forced-air facility, which was maintained at 23°C and 50%
relative humidity, with a 12 h/12 h light/dark cycle. The
mice were kept separately in single transparent cages mea-
suring 23.5 × 16.5 × 12 cm, and were allowed water and
rodent chow ad libitum. The experiments described in this
report were conducted in accordance with the “Guidelines
for Animal Experiments” of the institution (updated in
2007) [36], which are based on the National Institutes of
Health Guide for the Care and Use of Laboratory Animals,
and any pain experienced by the mice was minimized.
These guidelines were approved by the institutional ethics
committee for animal experiments [36]. All of the observa-
tions and evaluations were performed by a trained obser-
ver who was blinded to the treatment conditions and was
not informed of the treatment conditions in advance. Each
experimental group contained 10 mice.
Drug and stressor treatments
The protocols for the NC and stressor treatments were
determined based on preliminary experiments and pre-
vious studies examining their behavioral effects
[9,10,15,16]. With respect to the NC treatment, repeated
subcutaneous (s.c.) doses of NC which caused the depres-
sion-like behaviors most effectively were selected: a single
s.c. dose of 0.3 mg/kg was administered daily for 4 days
[9,10]. NC (Nacalai Tesque, Inc., Kyoto, Japan) was sup-
plied in free-base form at 95% purity, and was freshly dis-
solved in saline to a volume of 5 ml/kg immediately before
each administration. With respect to the stressor, treat-
ments using IM, which have been demonstrated to cause
depression-like behavioral effects, were used based on pre-
vious studies in rodent depression models [16]. In the pre-
sent experiments, repeated IM treatments in which the
peak effects were almost equivalent to the NC treatments
in preliminary experiments were selected: 10 min of IM,
which was induced by placing the mouse in a narrow
space (diameter about 12 cm) in a vinyl bag with some
breathing holes, was given once per day for 4 days.
The TRPV1 ligands capsaicin (CP), olvanil (OL), capsa-
zepine (CZ), anandamide (arachidonylethanolamide:
AEA), N-arachidonyldopamine (NADA), and arvanil (AR)
were purchased from Tocris Cookson Inc. (Ellisville, Mis-
souri, USA). With respect to the doses of the TRPV1
ligands, the doses for the repeated administrations were
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ments [27,29,33-35]. For each drug, the data were col-
lected and shown for those intraperitoneal (i.p.) doses
which induced no toxic behavioral alterations by them-
selves at the present time point: 0.1, 1 and 2.5 mg/kg for
CP, 0.1, 1 and 2.5 mg/kg for OL, 0.1, 1 and 5 mg/kg for
CZ, 0.1, 1 and 10 mg/kg for AEA, 0.1, 1 and 10 mg/kg for
NADA, and 0.1, 1 and 2.5 mg/kg for AR. The TRPV1
ligands were administered 60 min before each NC or IM
treatment, based on previous studies and preliminary
experiments [10,37]. Furthermore, in the experiments
examining the role of TRPV1 and CB1 receptors, the
TRPV1 antagonist CZ and the CB1 antagonist AM 251
(N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophe-
nyl)-4-methyl-1H-pyrazole-3-carboxamide: AM), pur-
chased from Tocris Cookson Inc., were used in
combination with the effective TRPV1 ligands, based on
those doses causing behavioral effects [38,39].
Since the TRPV1 ligands are not soluble in water, they
were initially dissolved in dimethylsulphoxide (DMSO)
(Nacalai Tesque Inc.) to one-third of the total volume, and
then diluted with distilled water to a volume of 5 ml/kg.
Since AEA, NADA, and AR were provided in ethanol
solutions (Tocris Cookson Inc.), the ethanol was evapo-
rated immediately before use under nitrogen gas, and the
residues were initially dissolved in DMSO to one-third of
the total volume, and then diluted with distilled water to a
volume of 5 ml/kg [40,41]. The other TRPV1 ligands were
also dissolved or diluted in DMSO to one-third of the
total volume, and then diluted with distilled water to a
volume of 5 ml/kg. In the NC- and IM-only groups, a
mixed vehicle solution of DMSO and distilled water at the
same ratio as the TRPV1 ligand solutions was injected
instead of the TRPV1 ligands, 60 min before each NC or
IM treatment. In the TRPV1 ligand-only groups, the same
volumes of saline vehicle were injected instead of the s.c.
injection of NC. In the control group without any drug or
stressor treatment (control group), a control vehicle solu-
tion of DMSO and distilled water at the same ratio as the
TRPV1 ligand solutions was injected instead of the
TRPV1 ligands, and then the same volume of saline vehi-
cle was injected instead of the NC or IM treatment. The
drug and stressor treatments and each experimental ses-
sion were performed between 15 and 19 h of the light
cycle.
Forced swimming test
Based on previous studies [10,14,16], a glass cylinder appa-
ratus 33 cm in height and 18 cm in diameter containing
14 cm of water at 21-23°C was used for the forced swim-
ming test. Using the activity-measuring and recording sys-
tem Supermex-CompACT AMS instrument (Muromachi
Kikai Co. Ltd., Tokyo, Japan), for which an infrared sensor
was placed over the cylinder at a distance of 20 cm from
the water and the frequency of each mouse crossing the
area under the sensor while swimming was measured as
the number of counts, the “time until immobility”,t h e
time after when only modest swimming behaviors neces-
sary to avoid drowning (<60 counts/min under the present
conditions), as well as the “activity counts (per 10 min)”
which reflected the amount of swimming behaviors during
a 10 min experimental period, was monitored as a para-
meter of the test. Considering the time course of the beha-
vioral alterations [10], the evaluations of these parameters
were performed at the 2 h time point after the last NC or
IM treatment.
Tail suspension test
Based on previous studies [10,42], a cardboard cube appa-
ratus of 35 cm per side was used for the tail suspension
test. The front surface of the apparatus was open, and
each mouse was suspended by fixing its tail in the center
of the upper surface using a tail hanger and non-irritating
adhesive tape. As a parameter for the test, the total dura-
tion of immobility (“total immobility time”) during the 6
min experimental period was calculated. Considering the
time course of the behavioral alterations [10], the evalua-
tion of the parameter was performed at the 2 h time point
after the last NC or IM treatment.
Statistical analysis
The data obtained were subjected to a two-way analysis of
variance (ANOVA) for the factors NC or IM treatment ×
treatment using each TRPV1 ligand [29]. With respect to
the experiments examining the role of TRPV1 and CB1
receptors, the data obtained were subjected to a three-way
ANOVA for the factors NC or IM treatment × treatment
using each effective TRPV1 ligand × treatment using the
TRPV1 or CB1 antagonist [39]. For pairwise comparisons,
post-hoc Bonferroni tests were performed [10]. All of the
comparisons were performed using statistical software
packages ("Excel Statistics” from Social Survey Research
Information Co. Ltd. Inc., Tokyo, Japan). P values less
than 0.05 were considered to be statistically significant.
Results
Effects of TRPV1 ligands against NC- and IM-induced
depression-like behavioral alterations in the forced
swimming test
The NC- and IM-induced depression-like behavioral
alterations in the forced swimming test and the effects of
the TRPV1 ligands are shown in Figure 1. In the NC- and
IM-only groups, significantly attenuated “time until immo-
bility” and attenuated “activity counts”, i.e. the indices
which reflected both the overall activity during the swim
behaviors and the minimum activity after immobility, were
observed as compared to the control group. In both
NC and IM groups co-treated with CP (F(6, 108) = 3.46,
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108) = 3.22, P < 0.01), the ANOVA with a 3 (NC, IM ver-
sus vehicle) × 4 (three doses of each TRPV1 ligand versus
vehicle) factorial design revealed significant recoveries
from the attenuated activity counts as compared to the
NC- or IM-only group (Figure 1a, b, and 1f). On the other
hand, in those NC and IM groups co-treated with CZ,
AEA, or NADA, no significant interactions between the
NC or IM treatment and the CZ, AEA, or NADA treat-
ment were observed for either the times until immobility
or the activity counts (Figure 1c, d, and 1e). However,
each value was still significantly attenuated as compared
to the control group (not shown in the figures). In each
TRPV1 ligand-only group, no significant alterations for
any parameters as compared to the control group were
observed (white columns in Figure 1a-f).
Effects of TRPV1 ligands against NC- and IM-induced
depression-like behavioral alterations in the tail
suspension test
The NC- and IM-induced depression-like behavioral
alterations in the tail suspension test and the effects of the
TRPV1 ligands are shown in Figure 2. In the NC- and IM-
only groups, a significantly increased “total immobility
time” as compared to the control group was observed. In
both NC and IM groups co-treated with CP (F(6, 108) =
3.88, P < 0.01), OL (F(6, 108) = 3.70, P < 0.01), or AR (F(6,
108) = 4.21, P < 0.001), the ANOVA with a 3 (NC, IM ver-
sus vehicle) × 4 (three doses of each TRPV1 ligand versus
vehicle) factorial design revealed significant recoveries
from the increased total immobility times as compared to
the NC- or IM-only group (Figure 2a, b, and 2f). On the
other hand, in the NC and IM groups co-treated with CZ,
AEA, or NADA, no significant interactions between the
NC or IM treatment and the CZ, AEA, or NADA treat-
ment were observed (Figure 2c, d, and 2e). However, each
value was still significantly attenuated as compared to the
control group (not shown in the figures). In each TRPV1
ligand-only group, no significant alterations as compared
t ot h ec o n t r o lg r o u pw e r eo b s e r v e d( w h i t ec o l u m n si n
Figure 2a-f).
Examination of the role of TRPV1 and CB1 receptors
With respect to the effective “antidepressant-like” drugs
against the NC- and IM-induced behavioral alterations,
interactions with the TRPV1 antagonist CZ (1 and 5 mg/
kg) were examined for the TRPV1 agonists CP and OL,
and interactions with both CZ (1 and 5 mg/kg) and the
CB1 antagonist AM (1 and 2.5 mg/kg) were examined for
the TRPV1 and CB1 agonist AR, in order to investigate the
role of TRPV1 and CB1 receptors (Figure 3 and 4). In the
CP and OL treatment groups, the ANOVA with a 3 (NC,
IM versus vehicle) × 3 (two most effective doses of CP or
OL versus vehicle) × 3 (two doses of CZ versus vehicle)
factorial design revealed significant antagonistic interac-
tions for CZ with the CP- or OL-induced antidepressant-
like behavioral alterations in both the forced swimming
and the tail suspension tests as follows: F(4, 243) = 2.89,
P < 0.05 for the time until immobility (forced swimming
test), F(4, 243) = 7.12, P < 0.001 for the activity counts
(forced swimming test), and F(4, 243) = 5.28, P < 0.001 for
the total immobility time (tail suspension test) in the CP
treatment group; and F(4, 243) = 2.47, P < 0.05 for the
time until immobility, F(4, 243) = 6.86, P < 0.001 for the
activity counts, and F(4, 243) = 4.83, P < 0.001 for the total
immobility time in the OL treatment group. In the AR
group, however, no significant antagonistic interactions
with the AR-induced antidepressant-like behavioral altera-
tions were caused by either CZ or AM in the forced swim-
ming or the tail suspension test.
Discussion
Similar “depression-like” behavioral alterations between
NC and IM treatment groups
Consistent with a previous report [10], repeated NC doses
under the present conditions caused enhanced “depres-
sion-like” behavioral alterations (i.e. reduced swimming
behaviors in the forced swimming test and increased
immobility time in the tail suspension test) as compared
to the control group, similar to mice treated with a typical
depression-inducing stressor [15]. However, as mentioned
above, “antidepressant” effects for NC have also been
reported clinically [11], and were also observed in some
animal models [43-45]. In the present experimental model
using ICR mice, short-lasting antidepressant-like beha-
vioral alterations were also observed preliminarily at early
time points (within 15 min) in the NC treatment groups.
The occurrence of depression-like or antidepressant-like
effects has been reported to be dependent on the specific
animal strain and test [45]. It has also been predicted that
a characteristically rapid desensitization of the direct target
nAChRs, following their initial activation by NC, may yield
contradicting depression-related behavioral alterations
[45]. Furthermore, the NC-induced depression-related
behavioral alterations may occur in accordance with neu-
roendocrine alterations such as the levels of brain monoa-
mines and stress hormones, in which the time course
coincides at least partly with the neuroendocrine
responses caused by the depression-inducing stressors,
regardless of the behavioral outcome [46,47].
As for the two behavioral tests used for the examina-
tion of depression-related behavioral alterations, it has
been reported that the test batteries themselves cause dif-
ferent modifications in brain monoamine and plasma
corticosterone levels depending on the test time [48,49].
However, under the present experimental conditions, the
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Page 4 of 11Figure 1 NC- and IM-induced depression-related behavioral alterations and the effects of the six TRPV1 ligands in the forced
swimming test. The values for the time until immobility (min) and the activity counts (counts/10 min) at the 2 h time point after the last NC or
IM treatment are shown. The data represent means ± SD (n = 10 for each group). aa (p < 0.01): significant attenuation as compared to the
control group. B (p < 0.05), BB (p < 0.01): significant increase as compared to the NC- or IM-only group. The abbreviations of the co-
administered TRPV1 ligands captioned below the X-axis with each i.p. dose (mg/kg) are noted in the text. The data for the control, NC-only, IM-
only, and TRPV1 ligand-only groups are also shown.
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between the NC and IM groups, and were induced
equally in both the forced swimming and the tail suspen-
sion tests.
Effects of TRPV1 agonists vs. antagonists against NC-
induced depression-like behaviors
Against the NC-induced depression-like behavioral
alterations, as well as the IM-induced depression-like
behaviors, a significant “antidepressant” attenuation was
caused by the TRPV1 agonists CP and OL (Figure 1 and
2). Although the antidepressant-like effects of OL on
the forced swimming behaviors are consistent with the
data from a previous study [29], the antidepressant-like
modifications of TRPV1 agonists against the effects of
NC and IM have not been reported in representative
behavioral tests. Furthermore, for these antidepressant-
like effects, the involvement of TRPV1 receptors was
demonstrated by their attenuation using the TRPV1
antagonist CZ (Figure 3 and 4), which has also been
reported for the CP-induced hypolocomotor effects in
the open-field test [33]. The author’sd a t aa l s os t r o n g l y
support the contribution of TRPV1 receptors to the
NC- and IM-induced depression-like behavioral
alterations.
The TRPV1 antagonist CZ by itself did not provide
any significant effects against the NC- and IM-induced
depression-like behavioral alterations. Considering that a
blockade of TRPV1 receptors induced a reduced fear
memory suggestive of an impairment in stress-coping
[50] and anxiolytic-like behaviors via facilitating defen-
sive responses [51], direct behavioral alterations caused
by CZ could be predicted. However, in the present
experimental model, no significant direct interactions
were observed between CZ and the “depressogenic” NC
and IM.
Effects of cannabimimetic TRPV1 agonist against NC-
induced depression-like behaviors
AR, a synthetic “hybrid” a g o n i s to fT R P V 1a n dC B 1
receptors [35], also reduced the depression-like beha-
viors in both NC and IM groups for both tests. How-
ever, AEA and NADA, which function as both CB1 and
TRPV1 agonists but less potently as TRPV1 agonists as
Figure 2 NC- and IM-induced depression-related behavioral alterations and the effects of the six TRPV1 ligands in the tail suspension
test. The values for the total immobility time (min) at the 2 h time point after the last NC or IM treatment are shown. The data represent
means ± SD (n = 10 for each group). AA (p < 0.01): significant increase as compared to the control group. b (p < 0.05), bb (p < 0.01): significant
attenuation as compared to the NC- or IM-only group. The abbreviations of the co-administered TRPV1 ligands captioned below the X-axis with
each i.p. dose (mg/kg) are noted in the text. The data for the control, NC-only, IM-only, and TRPV1 ligand-only groups are also shown.
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Page 6 of 11Figure 3 Effects of the TRPV1 antagonist CZ or the CB1 antagonist AM against the depression-related behavioral alterations caused
by NC or IM plus an efficacious (antidepressant-like) TRPV1 ligand (CP, OL or AR) in the forced swimming test. Effects of CZ were
examined in the TRPV1 agonist CP, OL or AR treatment group (a-c). Effects of AM were examined in the CB1 (plus TRPV1) agonist AR treatment
group (d). The values for the time until immobility (min) and the activity counts (counts/10 min) at the 2 h time point after the last NC or IM
treatment are shown. The data represent means ± SD (n = 10 for each group). aa (p < 0.01): significant attenuation as compared to the control
group. B (p < 0.05), BB (p < 0.01): significant increase as compared to the NC- or IM-only group. c (p < 0.05), cc (p < 0.01): significant attenuation
as compared to the NC or IM plus an efficacious TRPV1 ligand (CP, OL or AR) group. The abbreviations of the co-administered TRPV1 ligands
with each antagonist captioned below the X-axis with each i.p. dose (mg/kg) are noted in the text.
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pressant-like effects. In the author’s preliminary study,
even for lower doses as well as higher doses sufficient to
cause toxic hypokinetic effects by i.p. injection, no
significant behavioral effects were observed. On the
other hand, previous studies have reported antidepres-
sant-like effects following the intraperitoneal administra-
tion of the fatty-acid amide hydrolase inhibitor URB59
Figure 4 Effects of the TRPV1 antagonist CZ or the CB1 antagonist AM against the depression-related behavioral alterations caused
by NC or IM plus an efficacious (antidepressant-like) TRPV1 ligand (CP, OL or AR) in the tail suspension test. Effects of CZ were
examined in the TRPV1 agonist CP, OL or AR treatment group (a-c). Effects of AM were examined in the CB1 (and TRPV1) agonist AR treatment
group (d). The values for the total immobility time (min) at the 2 h time point after the last NC or IM treatment are shown. The data represent
means ± SD (n = 10 for each group). AA (p < 0.01): significant increase as compared to the control group. bb (p < 0.01): significant attenuation
as compared to the NC- or IM-only group. C (p < 0.05), CC (p < 0.01): significant increase as compared to the NC or IM plus an efficacious
TRPV1 ligand (CP, OL or AR) group. The abbreviations of the co-administered TRPV1 ligands with each antagonist captioned below the X-axis
with each i.p. dose (mg/kg) are noted in the text.
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mate) and the endocannabinoid transport inhibitor
AM404 (N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosate-
traenamide), both of which enhance the levels of endo-
genous AEA [53,54]. Furthermore, a recent study
showed antagonistic effects for AM404 against the NC-
induced depression-like withdrawal symptoms via inter-
actions between the endocannabinoid and serotonergic
systems [55]. Although some direct CB1 agonists also
provided antidepressant-like effects depending on the
treatment conditions [54,56], it has been hypothesized
that these drugs, unlike URB59 and AM404 which acti-
vate only target CB1 receptor subpopulations where
endocannabinoids exert on-demand enhanced functions,
activate whole-brain CB1 receptors including those sub-
populations abolishing the antidepressant-related seroto-
nergic responses [56]. Further studies are needed with
respect to the effects of endogenous CB1 ligands, such
as AEA and NADA, against NC- and IM-induced
depression-like behaviors.
“Antidepressant-like” effects of AR, a synthetic hybrid
agonist for TRPV1 and CB1 receptors, against NC-induced
depression-like behaviors
It has been reported that AR activates TRPV1 receptors
with an efficacy at least comparable to that of CP [57].
Furthermore, it has also been reported that the potential
of AR to activate brain CB1 receptors is at least compar-
able to that of AEA [57]. Nevertheless, in the present
experimental model, the antidepressant-like effects of AR
against the NC- and IM-induced depression-like beha-
vioral alterations were not significantly blocked by the
TRPV1 antagonist CZ or the CB1 antagonist AM 251
(Figure 3 and 4). In a previous study, some neurobeha-
vioral alterations (e.g. catalepsy, attenuated spontaneous
activity, hypothermia, analgesia) caused by systemic AR
have been demonstrated to be unrelated to the activation
of TRPV1 or CB1 receptors by experiments using TRPV1
and CB1 antagonists [35]. With respect to these effects of
AR, the contributions of characteristic modifications in
receptor-coupled responses such as glutamate release
have been suggested [35,58]. However, the existence of
non-TRPV1 and non-CB1 receptor-related mechanisms
might be predictable, particularly against the complicated
behavioral effects induced by NC or IM, although addi-
tional experiments including studies using TRPV1 and/or
CB1 knockout mice are needed for the elucidation of the
detailed mechanisms responsible for the effects of AR.
Conclusions
TRPV1 receptors are known to participate in pain per-
ception [59], and little is known about the TRPV1-related
mechanisms underlying the depression-like behavioral
alterations caused by NC similar to those caused by IM.
Nevertheless, based on the results that the TRPV1 ago-
nists CP and OL attenuated the NC-induced depression-
like behavioral alterations, it is possible that TRPV1
receptors contribute, at least partially, to the NC-induced
“depression”. Further experimental studies are needed to
confirm the additional neuronal mechanisms underlying
the strong antidepressant-like effects of AR, which may
be therapeutically important for the treatment of NC
abuse.
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